Ammonium Lactate Lotion 12%*

Manufacturer
A-S Medication Solutions
Effective date
2023-08-24
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
3
Source
full-release
Hydrated at
2026-05-31 20:52:31

Label at a glance#

ProductAmmonium Lactate
Active ingredientAMMONIUM LACTATE
Label structure13 sections

Indications and uses

Ammonium Lactate Lotion is indicated for the treatment of dry, scaly skin (xerosis) and ichthyosis vulgaris and for temporary relief of itching associated with these conditions.

Dosage and administration

Shake well. Apply to the affected areas and rub in thoroughly. Use twice daily or as directed by a physician.

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

Rx only

For Dermatologic Use Only.
Not for Ophthalmic, Oral or Intravaginal Use.

DESCRIPTION

DESCRIPTION SECTION

*Ammonium Lactate Lotion, 12% specially formulates 12% lactic acid, as ammonium lactate to provide a lotion pH of 4.5 to 5.5. Ammonium Lactate Lotion also contains cetyl alcohol, glycerin, glyceryl monostearate, laureth-4, light mineral oil, magnesium aluminum silicate, methylcellulose, methylparaben, polyoxyethylene 100 stearate, polyoxyl stearate type II, propylene glycol, propylparaben, purified water, and for pH adjustment: lactic acid. Lactic acid is a racemic mixture of 2-hydroxypropanoic acid and has the following structural formula:

Chemical Structure
Chemical Structure

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

Lactic acid is an alpha-hydroxy acid. It is a normal constituent of tissues and blood. The alpha-hydroxy acids (and their salts) may act as humectants when applied to the skin. This property may influence hydration of the stratum corneum. In addition, lactic acid, when applied to the skin, may act to decrease corneocyte cohesion. The mechanism(s) by which this is accomplished is not yet known. An in vitro study of percutaneous absorption of Ammonium Lactate Lotion using human cadaver skin indicates that approximately 5.8% of the material was absorbed after 68 hours.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

Ammonium Lactate Lotion is indicated for the treatment of dry, scaly skin (xerosis) and ichthyosis vulgaris and for temporary relief of itching associated with these conditions.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Ammonium Lactate Lotion is contraindicated in those patients with a history of hypersensitivity to any of the label ingredients.

WARNINGS

WARNINGS SECTION

Sun exposure to areas of the skin treated with Ammonium Lactate Lotion, 12% should be minimized or avoided (see PRECAUTIONS section). The use of Ammonium Lactate Lotion should be discontinued if hypersensitivity is observed.

PRECAUTIONS

PRECAUTIONS SECTION

General

GENERAL PRECAUTIONS SECTION

For external use only. Stinging or burning may occur when applied to skin with fissures, erosions or that is otherwise abraded (for example, after shaving the legs). Caution is advised when used on the face because of the potential for irritation. The potential for post-inflammatory hypo- or hyperpigmentation has not been studied.

Information for Patients

INFORMATION FOR PATIENTS SECTION

Patients using Ammonium Lactate Lotion, 12% should receive the following information and instructions:

  1. This medication is to be used as directed by the physician, and should not be used for any disorder other than for which it was prescribed. It is for external use only. Avoid contact with eyes, lips, or mucous membranes.
  2. Patients should minimize or avoid use of this product on areas of the skin that may be exposed to natural or artificial sunlight, including the face. If sun exposure is unavoidable, clothing should be worn to protect the skin.
  3. This medication may cause transient stinging or burning when applied to skin with fissures, erosions, or abrasions (for example, after shaving the legs).
  4. If the skin condition worsens with treatment, the medication should be promptly discontinued.

Carcinogenesis, Mutagenesis, Impairment of Fertility

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

The topical treatment of CD-1 mice with 12%, 21% or 30% ammonium lactate formulations for two years did not produce a significant increase in dermal or systemic tumors in the absence of increased exposure to ultraviolet radiation. The maximum systemic exposure of the mice in this study was 0.7 times the maximum possible systemic exposure in humans. However, a long-term photocarcinogenicity study in hairless albino mice suggested that topically applied 12% ammonium lactate formulations enhanced the rate of ultraviolet light-induced skin tumor formation. The mutagenic potential of ammonium lactate formulations was evaluated in the Ames assay and in the mouse in vivo micronucleus assay, both of which were negative. In dermal Segment I and III studies with ammonium lactate formulations there were no effects observed in fertility or pre- or post-natal development parameters in rats at dose levels of 300 mg/kg/day (1800 mg/m2/day), approximately 0.4 times the human topical dose.

Pregnancy

PREGNANCY SECTION

Teratogenic effects

TERATOGENIC EFFECTS SECTION

Animal reproduction studies have been performed in rats and rabbits at doses up to 0.7 and 1.5 times the human dose respectively (600 mg/kg/day, corresponding to 3600 mg/m2/day in the rat and 7200 mg/m2/day in the rabbit) and have revealed no evidence of impaired fertility or harm to the fetus due to ammonium lactate formulations. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, Ammonium Lactate Lotion should be used during pregnancy only if clearly needed.

Nursing Mothers

NURSING MOTHERS SECTION

Although lactic acid is a normal constituent of blood and tissues, it is not known to what extent this drug affects normal lactic acid levels in human milk. Because many drugs are excreted in human milk, caution should be exercised when Ammonium Lactate Lotion is administered to a nursing woman.

Pediatric Use

PEDIATRIC USE SECTION

Safety and effectiveness of Ammonium Lactate Lotion have been demonstrated in infants and children. No unusual toxic effects were reported.

Geriatric Use

GERIATRIC USE SECTION

Clinical studies of Ammonium Lactate Lotion 12% did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between elderly and younger patients. In general, dose selection for an elderly patient should be cautious.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

The most frequent adverse experiences in patients with xerosis are transient stinging (1 in 30 patients), burning (1 in 30 patients), erythema (1 in 50 patients) and peeling (1 in 60 patients). Other adverse reactions which occur less frequently are irritation, eczema, petechiae, dryness and hyperpigmentation. Due to the more severe initial skin conditions associated with ichthyosis, there was a higher incidence of transient stinging, burning and erythema (each occurring in 1 in 10 patients).

OVERDOSAGE

OVERDOSAGE SECTION

The oral administration of Ammonium Lactate Lotion to rats and mice showed this drug to be practically non-toxic (LD50>15 mL/kg).

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

Shake well. Apply to the affected areas and rub in thoroughly. Use twice daily or as directed by a physician.

HOW SUPPLIED

HOW SUPPLIED SECTION

Product: 50090-6587

NDC: 50090-6587-0 225 g in a BOTTLE, PLASTIC

SPL UNCLASSIFIED SECTION

Mfd. by:
Taro Pharmaceuticals Inc.
Brampton, Ontario,
Canada L6T 1C1

Dist. by:
Taro Pharmaceuticals
U.S.A., Inc.

Hawthorne, NY 10532
Revised: July 2022

AMMONIUM LACTATE

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Label Image
Label Image

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
197362ammonium lactate 12 % Topical LotionPSN3
197362ammonium lactate 120 MG/ML Topical LotionSCD3
197362ammonium lactate 12 % Topical LotionSY3
197362ammonium lactate 120 MG/ML (as neutralized lactic acid 12 % ) Topical LotionSY3

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
LACTIC ACID, UNSPECIFIED FORM Pharmacologic Class Indexing1Indexing - Pharmacologic Class20220121

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
f52be47f-7aa7-46c0-b1fa-50c18dd50206Product name120201029
444b3e50-f226-46ef-bfca-2e7035d140cdProduct name120190611
7cda52fc-125f-421c-8fea-bc1974370c49Product name220180703
597b1cfd-7b31-5048-62be-ca5cd740da2fProduct name120140508
ec2149b3-5c6d-5344-f757-c86411073075Product name120140508

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
50090-6587-0Ammonium Lactate225 g in 1 BOTTLE, PLASTICLOTION2253

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
50090-6587AMMONIUM LACTATE LOTION [A-S MEDICATION SOLUTIONS]3Current NDC, 1 package rows20230825_ab54704d-ace2-410c-b0af-2fa13462a8b3.zip

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
50090-6587-0GM - Gram50090-65876ba9b9b8-24d0-4fc6-9ce5-e2bd2a62f59b12023-09-05
51672-1300-5GM - Gram51672-1300f3e5b834-7369-4e84-9ce1-821a26e0aa2512012-07-24
51672-1300-9GM - Gram51672-1300e7b6d29c-e373-44ab-a3cb-3ad3b3cee0d712012-07-24

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 14 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
50090-658750090-6587-0
51672-1300

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 13 matching rows.

Source Document#

Source XML

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 44.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A076216-001AMMONIUM LACTATEAMMONIUM LACTATEEQ 12% BASELOTION / TOPICALAB2004-05-28

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 1 matching rows.

Application-product, TE code table
Application-productTE code
A076216-001AB

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 44 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-10-15 13:18:302026-09A076216-001AMMONIUM LACTATEEQ 12% BASELOTION / TOPICALAB2004-05-28c2088c7a36db…
2026-09-14 22:38:342026-08A076216-001AMMONIUM LACTATEEQ 12% BASELOTION / TOPICALAB2004-05-2884e616aacf4f…
2026-08-18 06:07:402026-07A076216-001AMMONIUM LACTATEEQ 12% BASELOTION / TOPICALAB2004-05-28caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A076216-001AMMONIUM LACTATEEQ 12% BASELOTION / TOPICALAB2004-05-28011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A076216-001AMMONIUM LACTATEEQ 12% BASELOTION / TOPICALAB2004-05-2831067a03dcf5…
2025-08-23 18:47 UTC2025-08A076216-001AMMONIUM LACTATEEQ 12% BASELOTION / TOPICALAB2004-05-286a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A076216-001AMMONIUM LACTATEEQ 12% BASELOTION / TOPICALAB2004-05-28fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A076216-001AMMONIUM LACTATEEQ 12% BASELOTION / TOPICALAB2004-05-28b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A076216-001AMMONIUM LACTATEEQ 12% BASELOTION / TOPICALAB2004-05-2803ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A076216-001AMMONIUM LACTATEEQ 12% BASELOTION / TOPICALAB2004-05-282680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A076216-001AMMONIUM LACTATEEQ 12% BASELOTION / TOPICALAB2004-05-285bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A076216-001AMMONIUM LACTATEEQ 12% BASELOTION / TOPICALAB2004-05-28d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A076216-001AMMONIUM LACTATEEQ 12% BASELOTION / TOPICALAB2004-05-28d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A076216-001AMMONIUM LACTATEEQ 12% BASELOTION / TOPICALAB2004-05-2879d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A076216-001AMMONIUM LACTATEEQ 12% BASELOTION / TOPICALAB2004-05-28301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A076216-001AMMONIUM LACTATEEQ 12% BASELOTION / TOPICALAB2004-05-281e350fbaab3a…
2024-05-31 18:47 UTC2024-05A076216-001AMMONIUM LACTATEEQ 12% BASELOTION / TOPICALAB2004-05-288072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A076216-001AMMONIUM LACTATEEQ 12% BASELOTION / TOPICALAB2004-05-285c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A076216-001AMMONIUM LACTATEEQ 12% BASELOTION / TOPICALAB2004-05-285d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A076216-001AMMONIUM LACTATEEQ 12% BASELOTION / TOPICALAB2004-05-284b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A076216-001AMMONIUM LACTATEEQ 12% BASELOTION / TOPICALAB2004-05-2874a2ff9319b5…
2022-03-09 01:35 UTC2022-03A076216-001AMMONIUM LACTATEEQ 12% BASELOTION / TOPICALAB2004-05-28bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A076216-001AMMONIUM LACTATEEQ 12% BASELOTION / TOPICALAB2004-05-28782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A076216-001AMMONIUM LACTATEEQ 12% BASELOTION / TOPICALAB2004-05-2887673890dc5c…
2021-03-12 10:30 UTC2021-03A076216-001AMMONIUM LACTATEEQ 12% BASELOTION / TOPICALAB2004-05-285aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A076216-001AMMONIUM LACTATEEQ 12% BASELOTION / TOPICALAB2004-05-288869cabd3fbd…
2020-11-12 02:37 UTC2020-11A076216-001AMMONIUM LACTATEEQ 12% BASELOTION / TOPICALAB2004-05-28c0c555d07b60…
2019-12-14 00:12 UTC2019-12A076216-001AMMONIUM LACTATEEQ 12% BASELOTION / TOPICALAB2004-05-283f01610625f2…
2019-09-15 20:21 UTC2019-09A076216-001AMMONIUM LACTATEEQ 12% BASELOTION / TOPICALAB2004-05-28b00525d2431f…
2019-07-19 19:46 UTC2019-07A076216-001AMMONIUM LACTATEEQ 12% BASELOTION / TOPICALAB2004-05-28ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A076216-001AMMONIUM LACTATEEQ 12% BASELOTION / TOPICALAB2004-05-286a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A076216-001AMMONIUM LACTATEEQ 12% BASELOTION / TOPICALAB2004-05-281c564ffb4f44…
2023-12-20 04:57 UTC2023-12A076216-001AMMONIUM LACTATEEQ 12% BASELOTION / TOPICALAB2004-05-28ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A076216-001AMMONIUM LACTATEEQ 12% BASELOTION / TOPICALAB2004-05-28a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A076216-001AMMONIUM LACTATEEQ 12% BASELOTION / TOPICALAB2004-05-289b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A076216-001AMMONIUM LACTATEEQ 12% BASELOTION / TOPICALAB2004-05-28a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A076216-001AMMONIUM LACTATEEQ 12% BASELOTION / TOPICALAB2004-05-283f0d92c62455…
2023-05-13 08:27 UTC2023-05A076216-001AMMONIUM LACTATEEQ 12% BASELOTION / TOPICALAB2004-05-28053a50430f4f…
2023-01-26 05:58 UTC2023-01A076216-001AMMONIUM LACTATEEQ 12% BASELOTION / TOPICALAB2004-05-283bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A076216-001AMMONIUM LACTATEEQ 12% BASELOTION / TOPICALAB2004-05-283a93d1ddd44b…

Observed Orange Book normalized TE history#

Normalized TE history page 1 of 2 · 44 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2026-10-15 13:18:302026-09A076216-001AB1c2088c7a36db…
2026-09-14 22:38:342026-08A076216-001AB184e616aacf4f…
2026-08-18 06:07:402026-07A076216-001AB1caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A076216-001AB1011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A076216-001AB131067a03dcf5…
2025-08-23 18:47 UTC2025-08A076216-001AB16a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A076216-001AB1fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A076216-001AB1b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A076216-001AB103ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A076216-001AB12680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A076216-001AB15bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A076216-001AB1d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A076216-001AB1d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A076216-001AB179d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A076216-001AB1301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A076216-001AB11e350fbaab3a…
2024-05-31 18:47 UTC2024-05A076216-001AB18072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A076216-001AB15c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A076216-001AB15d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A076216-001AB14b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A076216-001AB174a2ff9319b5…
2022-03-09 01:35 UTC2022-03A076216-001AB1bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A076216-001AB1782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A076216-001AB187673890dc5c…
2021-03-12 10:30 UTC2021-03A076216-001AB15aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A076216-001AB18869cabd3fbd…
2020-11-12 02:37 UTC2020-11A076216-001AB1c0c555d07b60…
2019-12-14 00:12 UTC2019-12A076216-001AB13f01610625f2…
2019-09-15 20:21 UTC2019-09A076216-001AB1b00525d2431f…
2019-07-19 19:46 UTC2019-07A076216-001AB1ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A076216-001AB16a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A076216-001AB11c564ffb4f44…
2023-12-20 04:57 UTC2023-12A076216-001AB1ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A076216-001AB1a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A076216-001AB19b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A076216-001AB1a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A076216-001AB13f0d92c62455…
2023-05-13 08:27 UTC2023-05A076216-001AB1053a50430f4f…
2023-01-26 05:58 UTC2023-01A076216-001AB13bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A076216-001AB13a93d1ddd44b…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 2 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
Ammonium LactateAMMONIUM LACTATESun Pharmaceutical Industries, Inc.8bb09bb3-5bbc-489d-96c1-ae97cb58381e2026-07-30Warnings, Adverse reactionsExact identifier
ndc (product): 51672-1300
Ammonium LactateAMMONIUM LACTATEA-S Medication Solutionsab54704d-ace2-410c-b0af-2fa13462a8b32023-08-24Warnings, Adverse reactionsExact identifier
ndc (package): 50090-6587-0
ndc (product): 50090-6587
ndc11 (package): 50090658700
spl id: 261e2c03-7495-4a76-aebe-8e7c795cb8e5
spl set id: ab54704d-ace2-410c-b0af-2fa13462a8b3

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.